ClinicalTrials.gg
RecruitingNCT06757309VIHMEDUpdated Jan 3, 2025

Impact of Mediterranean Diet in Cardiovascular Risk Among People With HIV

An interventional study of Mediterranean Diet in HIV Infection, Inflammation and Cardiovascular Risk, sponsored by Parc de Salut Mar. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-03.

Sponsored by Parc de Salut Mar · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 262 studies in HIV Infections with a site in Spain — 11 open to participants now, 21 under way, 8 of them phase 3. HIV Infections · Spain.

Planned enrollment
139th of 230
64 · median 100
Started
2024
with 3 others
No phase
10 of 262
5 open now
Primary completion
2025-12
later than 10 of 20 live
Registered
257th of 262
by date

Among the 262 studies in HIV Infections with a site in Spain, this one is the 139th largest by planned enrollment of the 230 interventional ones that give a count, is one of 4 that started in 2024, is one of 10 with no phase, reaches primary completion later than 10 of the 20 other live ones, and was the 257th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

11 of the 262 studies in HIV Infections with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in HIV Infections with a site in Spain, or all of them as a file.
02

Study summary

This study (VIHMET) aims to explore how dietary changes, specifically the adoption of a Mediterranean diet, can improve health outcomes in people living with HIV (PLWH) who are on antiretroviral therapy (ART). PLWH often experience chronic inflammation, metabolic disturbances, and elevated cardiovascular risk due to the virus, immune activation, and ART-related side effects. By examining dietary interventions, this study seeks strategies to reduce these risks and enhance quality of life.

The VIHMET study is a randomized clinical trial involving 64 participants at Hospital del Mar, Barcelona, randomized into control and intervention groups (1:2 ratio). The intervention group will receive personalized nutritional counseling to improve adherence to the Mediterranean diet, focusing on food selection and meal preparation. The control group will follow standard dietary recommendations. Assessments will occur at baseline, week 24, and week 48.

Key health indicators include lipid profiles, markers of inflammation, immune activation, and cardiovascular health, assessed through non-invasive techniques like arterial stiffness and subclinical atherosclerosis measurements. Participants will complete questionnaires on diet adherence, physical activity, and quality of life, alongside anthropometric evaluations.

Eligible participants are adults with HIV, undetectable viral loads for 12+ months, and elevated LDL cholesterol with low Mediterranean diet adherence. Exclusion criteria include lipid-lowering drugs, chronic anti-inflammatory therapy, or other active inflammatory/metabolic conditions.

This study aims to improve lipid levels, reduce inflammation, decrease arterial stiffness, and assess diet adherence's impact on quality of life and subclinical atherosclerosis. Results may inform dietary recommendations to reduce cardiovascular risks and enhance holistic care for PLWH.

Read the detailed description

The VIHMET study aims to investigate the role of dietary optimization, specifically adopting a Mediterranean diet, in improving metabolic health, reducing immune activation, and mitigating cardiovascular risks in people living with HIV (PLWH) who are on antiretroviral therapy (ART). PLWH face unique challenges, including chronic immune activation and increased inflammation, which contribute to accelerated aging, metabolic complications, and a higher prevalence of cardiovascular disease (CVD) compared to the general population. This study hypothesizes that dietary interventions may reduce these risks, leading to better overall health outcomes.

Study Design

This randomized, prospective, open-label interventional study will recruit 64 participants from the HIV outpatient clinic at Hospital del Mar in Barcelona. Participants will be randomized into two groups: an intervention group and a control group ( 1 SoC:2 intervention ratio). The intervention group will receive personalized counseling to improve adherence to the Mediterranean diet, while the control group will receive general dietary recommendations. Each participant will be followed for 48 weeks, with clinical and laboratory evaluations conducted at baseline, week 24, and week 48.

Study Objectives

Primary Objectives:

To evaluate changes in lipid profiles (total cholesterol, LDL, HDL, and triglycerides) at weeks 24 and 48.

To assess reductions in immune activation markers and inflammatory cytokines, such as IL-6, TNF-alpha, and sCD14.

To measure improvements in arterial stiffness using pulse wave velocity (PWV) as an indicator of subclinical CVD.

To assess the impact of the intervention on adherence to the Mediterranean diet using the MEDAS score.

Secondary Objectives:

To evaluate changes in quality of life using the EQ-5D questionnaire. To analyze changes in body composition, including BMI, waist circumference, and weight.

To assess reductions in TMAO (trimethylamine-N-oxide), a biomarker linked to CVD risk.

To investigate the presence and composition of coronary atherosclerosis using non-invasive coronary CT angiography (CCTA).

Participant Eligibility

Inclusion Criteria:

Adults aged 18 years or older. Confirmed HIV diagnosis. On stable ART with an undetectable viral load for at least 12 months. LDL cholesterol >140 mg/dL. Mediterranean Diet Adherence Screener (MEDAS) score \<9, indicating low adherence.

Exclusion Criteria:

Use of lipid-lowering medications or chronic anti-inflammatory drugs. Active hepatitis B or C or other chronic inflammatory conditions. Familial hypercholesterolemia. Uncontrolled hypothyroidism or diabetes mellitus. Inability to provide informed consent.

Interventions Ratio: 1 SoC : 2 intervention

Intervention Group: Participants in the intervention group will undergo tailored nutritional counseling focusing on the Mediterranean diet. Key components include:

Education on food selection and preparation, emphasizing fruits, vegetables, whole grains, olive oil, nuts, and fish.

Guidance on reducing saturated fats and sugars. Development of individualized meal plans considering dietary habits and socioeconomic status.

Scheduled virtual follow-ups at weeks 4 and 12 to review adherence and address challenges.

Control Group: Participants will receive general dietary advice provided through standard informational leaflets. No individualized or follow-up counseling will be provided.

Outcome Measures

Primary Outcomes:

Changes in lipid profiles (total cholesterol, LDL, HDL, and triglycerides) at week 24 and 48 respect to baseline Reductions in inflammatory and immune activation markers (IL-6, TNF-alpha, sCD163, and sCD14) at week 24 and 48 respect to baseline Improvements in arterial stiffness as measured by PWV at week 24 and 48 respect to baseline

Secondary Outcomes:

Improvements in MEDAS scores, indicating better adherence to the Mediterranean diet at week 24 and 48 respect to baseline Changes in TMAO levels, reflecting reduced CVD risk at week 24 and 48 respect to baseline Alterations in quality of life (EQ-5D scores) at week 24 and 48 respect to baseline Presence and composition of coronary plaques using CCTA.

Procedures and Assessments

Participants will attend clinical visits at baseline, week 24, and week 48. The following assessments will be conducted:

Clinical Data Collection:

Medical history, HIV-related parameters, and medication use. Anthropometric Measurements: BMI, waist circumference, and weight. Dietary Adherence: MEDAS score and food frequency questionnaires. Laboratory Tests: Lipid profiles, inflammatory markers, immune activation biomarkers, and TMAO levels.

Imaging: Pulse wave velocity and CCTA to evaluate arterial health and coronary plaque burden.The study aims to demonstrate the benefits of dietary interventions in reducing CVD and metabolic risks, offering a holistic approach to HIV care that integrates nutritional counseling for long-term health improvements.

Statistical Analysis

Data will be analyzed using appropriate statistical methods. Continuous variables will be expressed as means and standard deviations, while categorical variables will be reported as frequencies. Comparisons between groups will be performed using t-tests or non-parametric equivalents, depending on data distribution. Multivariate regression models will assess the independent effects of dietary intervention on primary and secondary outcomes. All analyses will be conducted using Stata software, and a p-value \<0.05 will be considered statistically significant. A sample size of 60 participants (40 in the intervention group and 20 in the control group) provides adequate power to detect clinically significant changes in LDL cholesterol and other outcomes.

Ethical Considerations

The study adheres to the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines. All participants will provide written informed consent, and data confidentiality will be maintained according to GDPR standards. Participants will not receive financial compensation but will benefit from detailed health assessments and personalized dietary guidance.

Expected Impact

This study is expected to provide valuable insights into the role of dietary optimization in reducing cardiovascular and metabolic risks in PLWH. By addressing chronic inflammation, lipid disturbances, and immune activation, the findings could inform new strategies for integrating dietary counseling into HIV care. Such an approach emphasizes a holistic perspective, considering not only virological control but also long-term health and quality of life. The VIHMET study could represent a significant step forward in personalized care for PLWH, with potential applications in broader chronic disease management.

03

Conditions studied

  • HIV Infection
  • Inflammation
  • Cardiovascular Risk
  • Mediterranean Diet

Keywords

  • HIV
  • Inflammation
  • Coronary Artery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • Confirmed diagnosis of infection.
  • On stable antiretroviral therapy (ART) with an undetectable viral load for at least 12 months.
  • LDL cholesterol levels >140 mg/dL.
  • Low adherence to the Mediterranean diet, defined by a MEDAS score \<9.
  • Must be able to swallow tablets
  • Willingness and ability to provide .

Exclusion criteria

Exclusion Criteria:

  • Use of lipid-lowering medications.
  • Chronic use of anti-inflammatory drugs.
  • Active or infection.
  • Other chronic inflammatory conditions (e.g., diseases).
  • Familial hypercholesterolemia.
  • Uncontrolled metabolic conditions, such as hypothyroidism or diabetes mellitus.
  • Pregnancy or breastfeeding.
  • Cognitive or psychological conditions impairing the ability to comply with the study protocol.
  • Inability to provide .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • No intervention
    Standard of Care

    Standard of care arm will be the management as currently is provided. It provides participants with general dietary advice through informational leaflets. No personalized counseling or follow-up sessions are included. Participants continue their usual diet, receiving only baseline and routine assessments without additional support to modify their dietary habits or improve adherence to healthier eating patterns.

  • Experimental
    Intervention

    Intervention consists in personalized counseling to adopt the Mediterranean diet, focusing on whole foods, healthy fats, and lean proteins. Participants receive tailored meal plans, educational materials, and practical tips. Follow-up sessions at weeks 4 and 12 offer support, progress reviews, and goal-setting to ensure adherence and improved health outcomes.

    Behavioral: Mediterranean Diet

Interventions

  • BehavioralMediterranean Diet

    Intervention consists in personalized counseling to adopt the Mediterranean diet, focusing on whole foods, healthy fats, and lean proteins. Participants receive tailored meal plans, educational materials, and practical tips. Follow-up sessions at weeks 4 and 12 offer support, progress reviews, and goal-setting to ensure adherence and improved health outcomes

06

What researchers measure

Primary outcomes

  1. Change in LDL profile between groups

    Difference in the mean change (mg/dL) in LDL cholesterol between the intervention group and the standard of care (SoC) group at week 24, relative to baseline values.

    Time frame: 24 weeks

  2. Changes in HDL cholesterol

    Difference in the mean change (mg/dL) in HDL cholesterol between the intervention group and the standard of care (SoC) group at week 24, relative to baseline values.

    Time frame: week 24 respec to baseline

  3. Changes in body mass index

    Difference in the mean change in body Mass Index between the intervention group and the standard of care (SoC) group at week 24, relative to baseline values.

    Time frame: 24 weeks

  4. Changes in very low density lipoprotein by spectral MRI

    Difference in the mean change in very low lipoprotein between the intervention group and the standard of care (SoC) group at week 24, relative to baseline values measured by spectral MRI

    Time frame: 24 weeks

Secondary outcomes

  1. Changes in CD38+CD4+T-cell

    Difference in the mean percentage change in CD38+CD4+ T-cell levels between the intervention group and the standard of care (SoC) group at week 24, relative to baseline values, as measured by flow cytometry.

    Time frame: 24 weeks

  2. Changes in CD38+CD8+T-cell

    Difference in the mean percentage change in CD38+CD8+T-cell levels between the intervention group and the standard of care (SoC) group at week 24, relative to baseline values, as measured by flow cytometry.

    Time frame: 24 weeks

  3. change in Exhaustion CD4 T-cells

    Difference in the mean percentage change in PD1+CD4+T-cells levels between the intervention group and the standard of care (SoC) group at week 24, relative to baseline values, as measured by flow cytometry.

    Time frame: 24 weeks

  4. Changes in PD1+CD8+T-cells

    Difference in the mean percentage change in PD1+CD8+T-cells levels between the intervention group and the standard of care (SoC) group at week 24, relative to baseline values, as measured by flow cytometry.

    Time frame: week 24

  5. Change in Pulse wave velocity

    Difference in the mean percentage change in the Pulse Wave Velocity between the intervention group and the standard of care (SoC) group at week 24, relative to baseline values.

    Time frame: week 24

  6. Change in Pulse wave velocity 48w

    Difference in the mean percentage change in the Pulse Wave Velocity between the intervention group and the standard of care (SoC) group at week 48, relative to baseline values.

    Time frame: Week 48

  7. Changes in MEDAS score

    Difference in the mean percentage change in the MEDAS score between the intervention group and the standard of care (SoC) group at week 24, relative to baseline values.

    Time frame: 24 week

  8. changes in MEDAS score at week 48

    Difference in the mean percentage change in the MEDAS score between the intervention group and the standard of care (SoC) group at week 48, relative to baseline values.

    Time frame: Week 48

  9. Changes Quality of life measured by EQ-5D-3L at week 24

    Difference in the mean percentage change in score of Quality of life measured by EQ-5D-3L between the intervention group and the standard of care (SoC) group at week 24, relative to baseline values.

    Time frame: week 24

  10. Changes Quality of life measured by EQ-5D-3L at week 48

    Difference in the mean percentage change in score of Quality of life measured by EQ-5D-3L between the intervention group and the standard of care (SoC) group at week 48, relative to baseline values.

    Time frame: 48 weeks

  11. Changes in Calcium Score

    Difference in the mean percentage change in Calcium score Agatston between the intervention group and the standard of care (SoC) group at week 24, relative to baseline values, measured by angio-CT coronary scan.

    Time frame: week 24

  12. Changes in Calcium Score

    Difference in the mean percentage change in Calcium score Agatston between the intervention group and the standard of care (SoC) group at week 48,relative to baseline values, measured by angio-CT coronary scan.

    Time frame: 48 weeks

  13. Changes in Lipid core of the coronary plaque by week 24

    Difference in the mean percentage change in the lipid proportion of the coronary plaque between the intervention group and the standard of care (SoC) group at week 24 ,relative to baseline values, measured by angio-CT coronary scan.

    Time frame: Week 24

  14. Changes in the lipid core of the coronary plaque by week 48

    Difference in the mean percentage change in the lipid proportion of the coronary plaque between the intervention group and the standard of care (SoC) group at week 48 ,relative to baseline values, measured by angio-CT coronary scan.

    Time frame: 48 weeks

07

Study locations

1 of 1 sites recruiting
  • Hospital del Mar, Barcelona
    Barcelona, 08034, Spain
    Recruiting
    • Robert Güerri-Fernández, M.D. Ph.D. · Contactrguerri@hmar.org · +34932483251
    • Robert Güerri-Fernández, M.D. Ph.D. · Principal investigator
    • Juan José Chillarón, M.D. Ph.D. · Principal investigator
    • Esperanza Cañas-Ruano, M.D. · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — IPD will be shared on demand upon reasonable request, in compliance with ethical guidelines and applicable data protection regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.

Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 12 months is below that.

Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2024
First posted
Jan 3, 2025
StartActual
Dec 31, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Jul 2026
Last update
Jan 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06757309
Lead sponsor
Parc de Salut Mar
Responsible party
Sponsor
First posted
Jan 3, 2025
Start date
Dec 31, 2024
Primary completion
Dec 2025 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jan 3, 2025

Study contacts

Robert Güerri-Fernánderz, M.D. Ph.D.
Contact
rguerri@hmar.org
+34932483251
Juan Jose Chillaron, M.D. Ph.D.
Contact
jchillaron@psmar.cat
+34 932483251
Robert Güerri-Fernández, M.D. Ph.D.
study chair · Hospital del Mar
Juan Jose Chillarón-Jordan, M.D. Ph.D.
study chair · Hospital del Mar

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion